Revel engineers CMLase to reverse decades of protein glycation
Published in Nature Communications, the research shows the enzyme reduces CML by over seventy percent in aged human tissue.
See the latest news and media coverage for Revel. We track all announcements, press releases, and industry mentions in real time, all in one place.
Therapeutic enzyme developer targeting age-related damage
revelpharmaceuticals.comLast updated
Published in Nature Communications, the research shows the enzyme reduces CML by over seventy percent in aged human tissue.
The role focuses on lab operations and diseases of aging, seeking a motivated individual to join the team.
Research published in Nature Communications shows that molecule removes compounds associated with aging of tissues and could open the way for therapies against diseases related to...
Because no human enzyme reverses the modification, it accumulates in tissues. Researchers hope an enzyme that cleaves the modified amino acid could reduce some symptoms...
SAN FRANCISCO, March 17, 2022 (GLOBE NEWSWIRE) -- Revel Pharmaceuticals, a longevity therapeutics company developing enzymes to repair damage from aging, announced today that it...
Revel Pharmaceuticals recently announced it has raised $8.4 million in seed financing. The oversubscribed round was led by Kizoo Technology Capital, a...
Track Revel and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Revel and other trending companies.